Earnings ·
PTC Therapeutics reported second quarter 2026 financial results on July 30, 2026, posting total revenue of $361…
PTCTPtc Therapeutics, Inc.
PTC Therapeutics reported second quarter 2026 financial results on July 30, 2026, posting total revenue of $361 million and net income of $83.5 million. The company raised its full-year 2026 total revenue guidance to $1.18–$1.28 billion and product revenue guidance to $850–$950 million. Sephience generated $151.3 million in Q2 revenue, while the company received a $50 million milestone payment from Novartis for the initiation of the INVEST-HD Phase 3 study. Concurrently, PTC issued $550 million in senior convertible notes due in 2031 and repurchased existing 2026 notes. The company also appointed Hege Sollie-Zetlmayer to its Board of Directors. PTC Therapeutics is a biopharmaceutical company focused on discovering and commercializing medicines for rare genetic disorders.